Drug delivery development deal for Bespak:
This article was originally published in Clinica
Executive Summary
The developer of drug delivery technologies, Bespak (Milton Keynes), has agreed to collaborate with fellow UK company, Innovata Biomed (IB), the respiratory division of ML Laboratories, on the development of IB's C200 multi-dose dry powder inhaler device, used to deliver combination drug therapies for diseases such as asthma. Bespak will manufacture the devices on a pilot scale as required for the clinical trial of the therapy. According to ML Laboratories, IB has already found a European distributor - whose name was not disclosed - for the C200 inhaler, following "a multi-million pound licensing agreement".
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.